Retinal Vein Occlusion Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Retinal Vein Occlusion Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major retinal vein occlusion markets reached a value of US$ 2,656.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4,919.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.76% during 2024-2034.

The retinal vein occlusion market has been comprehensively analyzed in IMARC's new report titled "Retinal Vein Occlusion Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Retinal vein occlusion is a condition that mostly affects the blood vessels in the retina, which is the light-sensitive tissue covering the back of the eye. In this disease, one or more of the veins that carry blood further from the retina become blocked, disrupting normal blood flow. The common symptoms of the illness include sudden or gradual vision loss, blurring in the eye, distorted or wavy vision, and the appearance of floaters (dark spots or lines) in the visual field. In some cases, individuals suffering from this disorder may also experience pain or pressure in the eye. The diagnosis of the ailment typically consists of a combination of medical history assessment, physical examination, and various other investigations. A visual acuity test, which involves reading an eye chart to determine the sharpness and clarity of the vision, is also utilized among patients. The healthcare provider may further perform several blood workups to evaluate certain aspects that could contribute to the development of the disease, such as cholesterol levels, blood clotting factors, or inflammation markers.

The increasing cases of atherosclerosis, which causes artery narrowing and hardening due to the buildup of fatty deposits, thereby affecting the nearby veins, are primarily driving the retinal vein occlusion market. In addition to this, the rising incidences of various associated risk factors, including tobacco smoking, advancing age, certain systemic diseases, high blood pressure, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of anti-vascular endothelial growth factor (VEGF) drugs, such as ranibizumab, aflibercept, bevacizumab, etc., on account of their numerous advantages, like reducing edema, improving vision, and preventing neovascular complications, is further bolstering the market growth. Apart from this, the escalating application of local laser therapy, since it can be used to target specific areas of retinal swelling or ischemia to inhibit the progression of abnormal blood vessels, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intravitreal injections of steroids, which exert their anti-inflammatory action over an extended period, thereby enhancing treatment outcomes, is expected to drive the retinal vein occlusion market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the retinal vein occlusion market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for retinal vein occlusion and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the retinal vein occlusion market in any manner.


Recent Developments:
In February 2024, Annexin Pharmaceuticals AB reported that 6 out of 8 patients with the eye illness retinal vein occlusion who received the investigational drug candidate ANXV in Phase 2a/proof-of-concept study and were followed for three months or longer demonstrated long-term benefits without requiring multiple anti-VEGF injections.
In October 2023, Genentech reported that the U.S. FDA has granted approval for Vabysmo (faricimab-svoa) to treat individuals suffering from retinal vein occlusion. Vabysmo can help people maintain and improve their vision, with the added benefit of retinal dryness.

Key Highlights:
Retinal vein occlusion is the second most widespread retinal vascular condition, affecting 16.4 million people worldwide.
Retinal vein occlusion is often characterized as central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) based on the location of the blockage in the retinal vein.
As per the Blue Mountains Eye Study, the prevalence of BRVO and CRVO is 1.1% and 0.4%, respectively.
The incidence of retinal vein occlusion rises with age, with more than half of all incidents occurring in people older than 65.
The Blue Mountain Eye study found an incidence of 0.7% in persons less than 60 years old, increasing to 4.6% in patients 80 and older.

Drugs:
Lucentis refers to a vascular endothelial growth factor (VEGF) inhibitor developed by Genentech, a member of the Roche Group. It is intended to bind to and inhibit VEGF-A, a protein that is involved in the creation of new blood vessels and the hyperpermeability (leakiness) of existing vessels. Lucentis is FDA-approved to treat patients with macular edema following retinal vein occlusion (RVO).

ANXV is a novel investigational drug developed by Annexin Pharmaceuticals AB. This therapeutic candidate can immediately increase retinal blood flow, lower the risk of blindness, and provide various other short- and long-term advantages in the acute stage of retinal vein occlusion prior to the appearance of complications.

Faricimab is a dual Ang-2/VEGF-A inhibitor to treat patients with retinal vein occlusion. The medicine targets and inhibits two signaling pathways linked with numerous vision-threatening retinal diseases by neutralizing angiopoietin-2 (Ang-2) and VEGF-A.


Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the retinal vein occlusion market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the retinal vein occlusion market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:
This report also provides a detailed analysis of the current retinal vein occlusion marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:
Market Insights

How has the retinal vein occlusion market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the retinal vein occlusion market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the retinal vein occlusion market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of retinal vein occlusion across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinal vein occlusion by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of retinal vein occlusion by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with retinal vein occlusion across the seven major markets?
What is the size of the retinal vein occlusion patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of retinal vein occlusion?
What will be the growth rate of patients across the seven major markets?

Retinal Vein Occlusion: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for retinal vein occlusion drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the retinal vein occlusion market?
What are the key regulatory events related to the retinal vein occlusion market?
What is the structure of clinical trial landscape by status related to the retinal vein occlusion market?
What is the structure of clinical trial landscape by phase related to the retinal vein occlusion market?
What is the structure of clinical trial landscape by route of administration related to the retinal vein occlusion market?